Endogenous retroviruses expressed in human tumours cannot be used as targets for anti-tumour vaccines

Joachim Denner1

  • 1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany.

Translational Oncology
|November 22, 2020
PubMed

Insights

Many tumor cells express endogenous retroviral (ERV) proteins, suggesting their use in anti-tumor vaccines. However, current evidence lacks convincing proof of efficacy and raises concerns about potential harm from this strategy.

Area of Science:

  • Oncology
  • Immunology
  • Virology

Background:

  • Tumor cells often express proteins from endogenous retroviruses (ERVs) on their surface.
  • These ERV proteins are considered potential targets for anti-tumor vaccines.

Purpose of the Study:

  • To evaluate the efficacy of targeting endogenous retroviral antigens for anti-tumor vaccines.
  • To assess potential risks associated with using ERV-based anti-tumor immunotherapy.

Main Methods:

  • Review of existing data and literature on endogenous retroviruses and cancer immunotherapy.
  • Analysis of theoretical considerations regarding the immune response to ERV antigens in cancer patients.

Main Results:

  • Lack of convincing evidence supporting the efficacy of ERV-targeted anti-tumor vaccines.
  • Emerging concerns and theoretical considerations suggest this strategy may be detrimental.

Conclusions:

  • The therapeutic application of targeting endogenous retroviral antigens in cancer vaccines is not supported by current evidence.
  • Further research is needed to clarify the potential benefits and risks before clinical application.

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.8K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
706
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
13.7K